Iterum Therapeutics Plc (NASDAQ:ITRM)’s traded shares stood at 1.29 million during the last session, with the company’s beta value hitting 2.28. At the close of trading, the stock’s price was $1.43, to imply a decrease of -3.38% or -$0.05 in intraday trading. The ITRM share’s 52-week high remains $2.50, putting it -74.83% down since that peak but still an impressive 50.35% since price per share fell to its 52-week low of $0.71. The company has a valuation of $32.46M, with an average of 1.46 million shares in intraday trading volume over the past 10 days and average of 2.38 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Iterum Therapeutics Plc (ITRM), translating to a mean rating of 1.00. Of 1 analyst(s) looking at the stock, 0 analyst(s) give ITRM a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 1 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.2.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Iterum Therapeutics Plc (NASDAQ:ITRM) trade information
After registering a -3.38% downside in the last session, Iterum Therapeutics Plc (ITRM) has traded red over the past five days. The 5-day price performance for the stock is 17.21%, and 40.20% over 30 days. With these gigs, the year-to-date price performance is -27.41%. Short interest in Iterum Therapeutics Plc (NASDAQ:ITRM) saw shorts transact 2.53 million shares and set a 0.46 days time to cover.
Iterum Therapeutics Plc (ITRM) estimates and forecasts
Looking at statistics comparing Iterum Therapeutics Plc share performance against respective industry, we note that the company has outperformed competitors. Iterum Therapeutics Plc (ITRM) shares are -4.67% down over the last 6 months, with its year-to-date growth rate higher than industry average at 59.80% against 16.40%. Revenue is forecast to grow 33.30% this quarter before jumping 79.80% for the next one.
ITRM Dividends
Iterum Therapeutics Plc has its next earnings report out in December. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Iterum Therapeutics Plc (NASDAQ:ITRM)’s Major holders
Iterum Therapeutics Plc insiders hold 1.81% of total outstanding shares, with institutional holders owning 3.05% of the shares at 3.10% float percentage. In total, 3.05% institutions holds shares in the company, led by BLUE BELL PRIVATE WEALTH MANAGEMENT, LLC. As of 2024-06-30, the company held over 66.0 shares (or 0.0004% of shares), all amounting to roughly $76.0.
